The use of peripheral blood after G-CSF mobilization as a source of allogeneic hematopoietic stem cells (HSC) is increasing. [1] [2] [3] [4] The large number of HSC in such a graft could result in enhanced engraftment and accelerated hematopoietic recovery. 5 Immune reconstitution and overall alloreactivity after peripheral blood HSC transplantation (PBSCT) might also be significantly different than after BMT. 5, 6 Indeed, despite an increase in the number of donor T cells infused with a PBSC graft, the incidence of acute graft-versus-host disease (GVHD) appears to remain similar or less than after BMT. 5 However, a high risk of chronic GVHD has been suggested after allogeneic PBSCT. 7 In addition, several potentially lethal cases of severe cases of acute intra-vascular hemolysis have been described after PBSCT. [8] [9] [10] [11] [12] [13] These are due to the production of donorderived antibodies (Ab) directed against red blood cell (RBC) antigens (Ag) present on recipient RBC and not on donor RBC ('minor' ABO incompatibility). This suggests an influence of the HSC graft on post-transplantation immuno-hematological (IH) reconstitution. An analysis of the reported cases, summarized in Table 1 , reveals a number of interesting features. In addition to the presence of a 'minor' ABO incompatibility between donor and recipient and evidence for the production of donor-derived Ab directed at the Ag present on recipients' RBC, patients were also frequently transfused with recipient-compatible and donor-incompatible RBC. MTX was seldomly used in addition to cyclosporin A (CsA) for GVHD prophylaxis.
A multicenter randomized phase III clinical study comparing allogeneic BMT to allogeneic PBSCT (HLA-identical sibling donor) is presently being conducted by the French Society of Bone Marrow Transplantation (SFGM). 14 In this trial, GVHD prophylaxis includes both CsA and MTX. A survey of IH testing and transfusion practices among the participating transplantation centers revealed significant heterogeneity with, occasionally, transfusion practices likely to increase the risk of hemolysis after ABO 'minor' incompatible PBSCT. In order to homogenize and In addition, Bornhäuser et al 35 have described a case of acute hemolysis occurring at day 5 after an unrelated PBSCT with minor and major ABO incompatibility (donor B, recipient A). IH assessment at time of hemolysis was not reported.
enhance the quality of IH assessment and transfusion practices within our protocol as well as exclude patients considered at high risk for post-transplantation acute hemolysis, we elaborated proposals and submitted them to 25 allo-transplant French centers. Proposals included the following elements: pre-inclusion IH testing, IH exclusion criteria, transfusion rules, post-transplant IH surveillance and therapeutic attitude for hemolysis treatment. Analysis of responses to these proposals led to consensus determination and the elaboration of IH assessment and transfusion practice guidelines. These guidelines were approved and implemented by the SFGM.
Materials and methods
Proposals were drafted on the following elements: preinclusion IH testing, IH exclusion criteria, RBC transfusion rules, post-transplant IH surveillance and treatment of hemolysis. They were submitted to the 25 French centers practising allogeneic HSC. Twenty transplantation centers responded. Analysis and further discussions resulted in the determination of a consensus and the elaboration of recommendations which were approved and implemented by the SFGM. Details of the proposed recommendations as well as of the responses of the transplantation centers are available upon request from the authors.
Results

Pre-transplant IH assessment
Immuno-hematological assessment of donors and recipients prior to study inclusion should include ABO blood group determination (comprising A1 and A2 phenotype for blood group A patients), as well as RBC phenotype determination (Rh (D, C, E, c, e), Kell (K), Fya, Fyb, Jka, Jkb, S, s). In order to be interpretable, RBC phenotype should be determined prior to RBC transfusion. It is therefore recommended that such a determination be performed as soon as allogeneic HSC transplantation is considered. Furthermore, IH assessment of the donor and recipient prior to study inclusion, PBSCT donor before and after G-CSF administration as well as all recipients 1 day before transplantation should include anti-RBC Ab screening and titration. The Ab screening should include screening for Ab anti-A1 Ab for A2 or A2B donors and recipients as well as an indirect antiglobulin test at 37°C. The Ab titration should be performed with a standardized method (provided by Dr Le Pennec, Centre National de Recherche sur les Groupes Sanguins, Paris, France). A direct antiglobulin test (DAT) should be performed on donors and recipients prior to inclusion as well as on recipients 1 day before transplantation. Lastly, a crossmatch between recipient RBC and donor serum and vice versa, in the absence of ABO incompatibility between donor and recipient, is suggested but not mandatory prior to inclusion in the study as well as 1 day before transplantation.
Bone Marrow Transplantation
IH exclusion criteria for the SFGM protocol
The presence in the donor of anti-A Ab (group A or AB recipient) and/or anti-B Ab (group B or AB recipient) at a titer Ͼ1/32 and/or the presence in the donor of anti-RBC Ab directed against Rh (D, C, E, c, e), Kell (K), Fya, Fyb, Jka, Jkb, S, s Ag if present on recipient RBC are IH exclusion criteria in the protocol. If such anti-RBC Ab, not detected initially at the time of enrolment, are found the day before transplant, the graft should be washed prior to infusion.
RBC transfusion
ABO compatibility: ABO compatibility with both HSC donor and recipient (Table 2) is mandatory starting at day 0 of transplantation and, if feasible, as soon as the HSC donor is identified. In addition, a crossmatch between recipient serum and donor RBC is suggested but not mandatory.
Other RBC Ag compatibility ( 
Post-transplantation IH follow-up
The following tests should be performed twice a week from day 0 to day 15 and once a week from day 15 to day 30: (1) identification and titration of anti-RBC Ab (as described above); (2) DAT; (3) elution (even if the DAT is negative) using a standardized method (provided by Dr Le Pennec). In addition, the eluted product should be tested against a panel which includes A1, A2 and B RBC. The blood product should not contain hemolytic anti-A (a) and anti-B (b) Ab. When several choices are indicated, the choices are placed in order of preference. 
Immuno-hematological assessment if hemolysis is suspected
Hemolysis should be suspected in the presence of an unexplained inadequate post-transfusion increment and/or loss of у2 g/100 ml hemoglobin occurring in less than 24 h. In addition to standard biological hemolysis assessment, the following tests should be performed: (1) DAT and elution; (2) ABO Ag determination if incompatibility exists; (3) anti-RBC Ab titration.
Acute hemolysis treatment
In addition to standard treatment of acute hemolysis including forced diuresis and steroid treatment, erythropheresis or blood exchange should be considered.
Discussion
ABO incompatibility between donor and recipient is not a major obstacle to performing an allogeneic HSC transplantation. ABO incompatibility is termed 'minor' when the donor-derived anti-RBC Ab can recognize one or several RBC Ag present on recipient RBC. Conversely, an ABO incompatibility is said to be 'major' when the recipient has Ab recognizing AB Ag present on donor RBC. 15, 16 Hemolysis can result in the former case from an adverse interaction between residual recipient RBC and the donor immune system, and in the latter case, due to an adverse interaction between donor RBC and residual recipient immune system.
In the presence of a 'minor' ABO incompatibility, an immune-mediated hemolysis may occur by passive transfer of Ab at the time of allograft transfusion. Alternatively, it may occur subsequently, most often 1 to 3 weeks after transplantation, concomitant with the initiation of donorderived immune reconstitution. In the latter case, hemolysis is related to Ab production by donor-derived lymphocytes. Several risk factors have been associated with the occurrence of delayed hemolysis: T cell depletion, 17 FK 506 treatment, 18 absence of methotrexate to prevent GVHD 19, 20 or use of an unrelated donor BMT. 19 The use of PBSC as the source of allogeneic HSC graft is being increasingly considered and several randomized studies comparing a PBSC graft to a BMT graft are presently underway. 14, 21 In addition to the absence of general anesthesia for the donor, accelerated hematopoietic reconstitution as well as reduced transfusion requirements, as demonstrated in the autologous setting, 22 could be associated with the use of such an HSC source. Indeed, preliminary data from the randomized study conducted by the SFGM are very encouraging in these respects. 14 However, several cases of severe, potentially lethal immune-mediated acute hemolysis have been described after allogeneic PBSCT (Table 1 ). These occur 8 to 14 days after transplant and are associated with the recognition of residual recipient RBC by donor-derived Ab. Two factors, found in all published cases, could have contributed directly or indirectly to the occurrence of hemolysis: transfusion with donor-incompatible/recipient-compatible RBC and the use of CsA in the absence of MTX for GVHD prophylaxis.
The use of donor-incompatible/recipient-compatible RBC products will undoubtedly worsen an acute hemolysis mediated by donor-derived anti-recipient RBC Ab. However, the role of such a transfusion policy in initiating the hemolysis (at a time when plenty of residual recipient RBC are circulating) is less clear. Possibly, increased antigenicity of allogeneic 'ex-vivo'-maintained RBC vs residual endogenous recipient AB0-identical RBC could contribute.
As mentioned previously, the absence of MTX (in the presence of CsA) has previously been reported as a risk factor for delayed hemolysis. 19, 20 Methotrexate is cytotoxic for B lymphocytes. 23 The immunosuppressive effects of CsA are T cell-specific 24, 25 and the use of such a drug in the absence of MTX could result in enhanced B cell proliferation and a T cell-independent Ab response such as anti-RBC IgM isotype Ab production. In addition, a secondary T cell-dependent immune response (such as an IgG isotype anti-RBC Ab production) will not efficiently be prevented by CsA treatment. Interestingly, hemolysis with a similar mechanism has been described after organ transplantation using CsA for the prevention of graft rejection. [26] [27] [28] [29] [30] [31] Several quantitative and qualititative differences in a PBSC graft vs a marrow graft could contribute to enhancing the risk for acute immune-mediated hemolysis after PBSCT. An increased number of B cells, T cells and CD34 + present in a PBSC graft could result in an accelerated immune reconstitution with production of anti-recipient Ab early after transplantation at a time when significant numbers of recipient RBC are present. In addition, a G-CSFinduced TH2 cytokine profile of the T cells present in the graft 32, 33 could also contribute to enhancing post-PBSCT Ab responses. In the course of the SFGM randomized study, the phenotype and function of the immune cells present in the PBSC and BM grafts are being prospectively studied. Preliminary results indeed confirm a significant increase in the number of T cells (both CD4
+ and CD8 + ), B cells and monocytes in a PBSC graft as well as demonstrate a reduced IFN-gamma production by the cells present in the graft. 34 The elaboration and implementation of the guidelines described above have hopefully resulted in enhancing the quality as well as standardizing IH assessment and transfusion policies within the protocol. Requiring both donorand recipient-ABO/Rh Kell compatible RBC transfusion (or for CcEe Ag, donor-compatible if compatibility with both is impossible) as well as stressing aggressive IH assessment and acute hemolysis treatment are important features. However, one must stress that implementation of such transfusion practices will not totally prevent alloimmune-mediated hemolysis. Indeed, hemolysis of transfused group 0 RBC in minor ABO-incompatible unrelated donor BMT in patients receiving cyclosporin A without methotrexate has been described. 20 Because the presence in the donor of high anti-A and/or anti-B Ab titers and/or other hemolytic donor allo-Ab directed against host RBC Ag could be associated with a higher risk of post-PBSCT delayed hemolysis, the decision was made to exclude such transplantation from the protocol. However, as safety data are accumulated, in particular pertaining to the possible protective effect of MTX treatment and donor-compatible transfusion, this precaution might not be warranted in the future.
Finally, we found that the methodology we adopted with draft of proposals, submission to transplantation centers and consensus determination resulted not only in the elaboration and implementation of validated guidelines but also in initiating fruitful debates among HSC transplantation, transfusion medicine and IH specialists in France. Other aspects of transfusion medicine in the setting of HSC transplantation could also benefit from such an approach.
